Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.
about
Immunotherapy for the Adjunctive Treatment of Sepsis: From Immunosuppression to Immunostimulation. Time for a Paradigm Change?Immune Dysfunction as a Cause and Consequence of MalnutritionSepsis: From Pathophysiology to Individualized Patient CareImmunological monitoring to prevent and treat sepsisTolerance and Cross-Tolerance following Toll-Like Receptor (TLR)-4 and -9 Activation Are Mediated by IRAK-M and Modulated by IL-7 in Murine SplenocytesIdentification of biomarkers of response to IFNg during endotoxin tolerance: application to septic shockPreliminary results in quantitation of HLA-DRA by real-time PCR: a promising approach to identify immunosuppression in sepsis.Genetic susceptibility to Candida infections.IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1.Modulation of TNF-α mRNA stability by human antigen R and miR181s in sepsis-induced immunoparalysis.Early changes of the kinetics of monocyte trem-1 reflect final outcome in human sepsis.Granulocyte-macrophage colony stimulatory factor enhances the pro-inflammatory response of interferon-γ-treated macrophages to Pseudomonas aeruginosa infection.Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series.Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.Altered T Lymphocyte Proliferation upon Lipopolysaccharide Challenge Ex Vivo.Effect of Cholecalciferol Supplementation on Vitamin D Status and Cathelicidin Levels in Sepsis: A Randomized, Placebo-Controlled Trial.Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation.Short-term hyperoxia does not exert immunologic effects during experimental murine and human endotoxemia.Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view.Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation.CRIg-expressing peritoneal macrophages are associated with disease severity in patients with cirrhosis and ascites.Characterization of a model of systemic inflammation in humans in vivo elicited by continuous infusion of endotoxin.Sepsis and Immunosenescence in the Elderly Patient: A Review.Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome.Update in pulmonary infections 2012.Update in sepsis 2012.Sepsis induced immunosuppression: Implications for secondary infections and complications.Immunomodulatory adjuvant therapy in severe community-acquired pneumonia.Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases.IMMUNE CELL PHENOTYPE AND FUNCTION IN SEPSIS.Human leucocyte antigen (HLA-DR) gene expression is reduced in sepsis and correlates with impaired TNFα response: A diagnostic tool for immunosuppression?In vivo application of Granulocyte-Macrophage Colony-stimulating Factor enhances postoperative qualitative monocytic function.Role of cellular events in the pathophysiology of sepsis.Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?Frontline Science: HMGB1 induces neutrophil dysfunction in experimental sepsis and in patients who survive septic shock.Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.Noncanonical Fungal Autophagy Inhibits Inflammation in Response to IFN-γ via DAPK1.Detection of Serum Interleukin-6/10/18 Levels in Sepsis and Its Clinical Significance.Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis.Intermittent high-volume hemofiltration promotes remission in steroid-resistant idiopathic nephrotic syndrome.
P2860
Q22306306-D8D5D070-122A-405C-852A-CAF0BB7DFB5CQ26745474-072C031C-C6A5-4953-8550-BAE3D2EE7547Q26799911-776723FA-F01E-4C97-82D4-785683F0DF3DQ26851583-F7246AB6-7DF4-4D78-92EA-8C4715047EF2Q27302768-533F055D-F001-4724-BA2F-0C747D2F4ED9Q28534637-FB806DDB-6917-4415-A071-74A87A215238Q33753665-5A41CDD7-3FED-4CB3-88A0-AF9064F44527Q34341908-5CB027A3-6DD7-420C-97C7-2CF52BEDBDB6Q34981423-650E210E-66FB-405A-8F76-1240A4A2C719Q35084392-E659E556-9C1B-4A45-A5B3-10AA94A6CE11Q35104932-4FF7255D-EA39-414D-B59D-85F2828030B1Q35112889-E0FBAF96-9743-4D21-B2A2-45AA62D17837Q35131761-EEE08FDE-FD42-4833-AB82-E2BC6DD5A336Q35189328-18D151FB-1989-4A72-9F35-E984B0BBDE72Q35862468-0093DA8E-A58E-4097-A98E-986A61E7E158Q35957492-C2BC1BBD-9C57-437A-80F2-9132849A1CDAQ36054086-12D60E67-7BA4-41DA-B3B1-6E17797EA696Q36329532-94F787CF-260C-4D77-A2C3-40AC29D019C2Q36990515-1FD9AF1F-0394-4F2F-89EC-541309349C1CQ37088166-4EFA637D-C6E9-400F-9888-B524A267430AQ37277340-138EAA10-07C1-4D20-984C-A640CA9D1EE2Q37560603-F19DFD82-C81C-4B47-AAA0-7B684CE3D828Q37670488-414A6D12-42C4-433E-A257-782C4FB90266Q37690303-603D332B-BBF3-47F3-B1D2-B3312DEE4D72Q38106995-5CF006D0-DFF8-45E7-B288-00D56A8C3491Q38114486-3DB91549-42DB-4F41-ABB8-023B4D9456D5Q38148132-CAC13689-38EE-4F12-A1EF-8983F9913152Q38217723-F593DD12-5616-417A-9E8A-7F75E38FB5B1Q38304297-90CBA6CB-B3CD-4E1C-BD6F-1B91B2E2CD74Q38412875-A54C2883-40FE-4824-8F40-A5C6A98AB339Q38647570-0F4C784A-8EB1-40BB-AB64-000FCDB9A735Q38759043-58713B03-6FC9-4666-A3BA-CBAB76A9FA73Q38890353-B39333FE-67F4-42CC-B588-BF790CCCA906Q38935459-9CAB701B-F6E1-4841-B989-72A1E22AB0AAQ39103864-2D288D96-8722-4A99-AF0E-E93E9DF995FFQ39615420-20D30823-40B4-4CE4-8FDE-28F916E29FB9Q40434898-5E77D906-39D2-47A1-BF87-A85713AFEB81Q40481255-46BE2BDE-0E63-4561-ABC9-C462F84D2A7AQ40765104-D538B09D-B46E-4272-8D24-B363B1A917F0Q41433066-0315D72C-11C7-4759-9008-74344709B7A0
P2860
Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Reversal of immunoparalysis in ...... olled, randomized pilot study.
@en
Reversal of immunoparalysis in ...... olled, randomized pilot study.
@nl
type
label
Reversal of immunoparalysis in ...... olled, randomized pilot study.
@en
Reversal of immunoparalysis in ...... olled, randomized pilot study.
@nl
prefLabel
Reversal of immunoparalysis in ...... olled, randomized pilot study.
@en
Reversal of immunoparalysis in ...... olled, randomized pilot study.
@nl
P2093
P2860
P1476
Reversal of immunoparalysis in ...... olled, randomized pilot study.
@en
P2093
Frank Preijers
Jenneke Leentjens
Johannes G van der Hoeven
Leo A B Joosten
Matthijs Kox
Mihai G Netea
Peter Pickkers
Rebecca M Koch
P2860
P304
P356
10.1164/RCCM.201204-0645OC
P407
P577
2012-07-19T00:00:00Z